Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.
2.

HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.

Cardoso LP, Queiroz BB, Stefani MM.

J Clin Virol. 2009 Oct;46(2):134-9. doi: 10.1016/j.jcv.2009.07.009. Epub 2009 Aug 13.

PMID:
19682948
3.

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

Mulu A, Maier M, Liebert UG.

PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318. eCollection 2015.

4.

HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya.

Kiptoo M, Brooks J, Lihana RW, Sandstrom P, Ng'ang'a Z, Kinyua J, Lagat N, Okoth F, Songok EM.

BMC Infect Dis. 2013 Nov 4;13:517. doi: 10.1186/1471-2334-13-517.

5.

Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.

Yaotsè DA, Nicole V, Roch NF, Mireille PD, Eric D, Martine P.

Infect Genet Evol. 2009 Jul;9(4):646-52. doi: 10.1016/j.meegid.2009.04.002. Epub 2009 Apr 15.

PMID:
19460333
6.

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.

de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A; Madrid cohort of HIV-infected children.

J Antimicrob Chemother. 2011 Oct;66(10):2362-71. doi: 10.1093/jac/dkr305. Epub 2011 Aug 2.

PMID:
21810838
7.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
8.

Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced disease.

Soares EA, Makamche MF, Siqueira JD, Lumngwena E, Mbuagbaw J, Kaptue L, Asonganyi T, Seuánez HN, Soares MA, Alemnji G.

J Clin Virol. 2010 Jul;48(3):173-9. doi: 10.1016/j.jcv.2010.04.008. Epub 2010 May 18.

PMID:
20483657
9.

Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.

Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, Takou D, Nanfack A, Dori L, Torimiro J, Sarmati L, Andreoni M, Perno CF, Colizzi V, Cappelli G.

J Med Virol. 2012 May;84(5):721-7. doi: 10.1002/jmv.23244.

PMID:
22431019
10.

Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.

Xu S, Zhong P, Li J, Song A, Li H, Nie J, Li X, Wang Y.

Mol Diagn Ther. 2011 Feb 1;15(1):41-52. doi: 10.2165/11588860-000000000-00000.

PMID:
21469769
11.

Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.

Huruy K, Maier M, Mulu A, Liebert UG.

J Med Virol. 2015 Jun;87(6):978-84. doi: 10.1002/jmv.24110. Epub 2015 Feb 3.

PMID:
25649964
12.

Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.

Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, MacLeod W, Sanne I, Stevens WS.

PLoS One. 2016 Dec 1;11(12):e0166305. doi: 10.1371/journal.pone.0166305. eCollection 2016.

13.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

14.

Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.

Mulu A, Maier M, Liebert UG.

J Transl Med. 2015 Dec 1;13:377. doi: 10.1186/s12967-015-0734-3.

15.

Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women.

Reis MN, de Alcântara KC, Cardoso LP, Stefani MM.

J Med Virol. 2014 Jan;86(1):8-17. doi: 10.1002/jmv.23738. Epub 2013 Sep 13.

PMID:
24037943
16.

[Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].

Yalçınkaya T, Köse S.

Mikrobiyol Bul. 2014 Oct;48(4):585-95. Turkish.

17.

Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.

de Medeiros RM, Junqueira DM, Matte MC, Barcellos NT, Chies JA, Matos Almeida SE.

J Med Virol. 2011 Oct;83(10):1682-8. doi: 10.1002/jmv.22188.

PMID:
21837783
18.

HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania.

Kiwelu IE, Novitsky V, Kituma E, Margolin L, Baca J, Manongi R, Sam N, Shao J, McLane MF, Kapiga SH, Essex M.

PLoS One. 2014 Jul 8;9(7):e102258. doi: 10.1371/journal.pone.0102258. eCollection 2014.

19.

Prevalence and patterns of drug-resistance mutations among HIV-1 patients infected with CRF07_BC strains in Sichuan province, China.

Su L, Zhou X, Yuan D, Yang H, Wei D, Qin G, Liang S.

Virol Sin. 2014 Aug;29(4):237-41. doi: 10.1007/s12250-014-3487-x. Epub 2014 Aug 8.

PMID:
25160759
20.

Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.

Drescher SM, von Wyl V, Yang WL, Böni J, Yerly S, Shah C, Aubert V, Klimkait T, Taffé P, Furrer H, Battegay M, Ambrosioni J, Cavassini M, Bernasconi E, Vernazza PL, Ledergerber B, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

Clin Infect Dis. 2014 Jan;58(2):285-94. doi: 10.1093/cid/cit694. Epub 2013 Oct 21.

PMID:
24145874

Supplemental Content

Support Center